Matinas BioPharma Holdings, Inc.
MTNB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582554
No open-market purchases or sales by Matinas BioPharma Holdings, Inc. insiders were filed in the last 90 days; 25 institutions reported holding it in 13F filings for Q2 2026, worth $199.2K in total; no superinvestor holds it.
Key figures
- Market capCalculated value looks implausible
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 25
- 13F valueReported value at the end of Q2 2026
- $199.2K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$10.3M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 35.5K
- Shares sold short
- Change
- −13.9K
- −28.1% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding MTNB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MTNB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Matinas BioPharma Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Sanitam Partners LLC10% Owner | PPurchase | +3.60M | $0.586 | +$703.0K | –4.80M after | AmendedDerivative2 lots |
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Eide Robert J10% Owner | PPurchase | +2.52M | $0.586 | +$492.0K | –3.36M after | AmendedDerivative2 lotsDuplicate filing |
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Pembroke & Partners LLC10% Owner | PPurchase | +2.52M | $0.586 | +$492.0K | –3.36M after | AmendedDerivative2 lots |
Top 10 13F holders, Q2 2026
See all 25 holdersThe largest institutional positions in Matinas BioPharma Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 71,040 | $43.5K | 0.00% | +42,470+148.7% | Added |
| BlackRock, Inc. | 50,262 | $30.8K | 0.00% | +612+1.2% | Added |
| Geode Capital Management, LLC | 49,135 | $30.1K | 0.00% | −16,035−24.6% | Reduced |
| Vanguard Capital Management LLC | 40,110 | $24.5K | 0.00% | 00.0% | Unchanged |
| Holos Integrated Wealth LLC | 32,480 | $20.2K | 0.01% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 17,316 | $10.6K | 0.00% | −961−5.3% | Reduced |
| Susquehanna International Group, LLP | 16,093 | $9.85K | 0.00% | +1,765+12.3% | Added |
| Citadel Advisors LLC | 15,465 | $9.46K | 0.00% | −36,233−70.1% | Reduced |
| State Street Corp | 15,322 | $9.38K | 0.00% | 00.0% | Unchanged |
| Sargent Investment Group, LLC | 12,720 | $7.79K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of MTNB
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Matinas BioPharma Holdings, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Pembroke & Partners LLC | 13D/A | 9.99%16.9M shares | −10.01 ppfrom 20.00% | Feb 21, 20252 filings | Apr 10, 2025 | SEC |
| Sanitam Partners LLC | 13D/A | 9.99%2.97M shares | 0.00 ppfrom 9.99% | Feb 21, 20253 filings | Aug 13, 2026 | SEC |
| Lazar David E. | 13G | 9.81%545.0K shares | New | Aug 19, 20251 filing | Aug 19, 2025 | SEC |
| Hezbay Holdings LLC | 13G | 9.54%1.31M shares | +4.55 ppfrom 4.99% | Sep 25, 20252 filings | Jul 14, 2026 | SEC |